HealthCare Global Enterprises Limited (HCG) announced its unaudited financial results for the quarter and six months ended September 30, 2026, following approval by the Board of Directors at a meeting held on November 05, 2026. The disclosure is made pursuant to Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Consolidated Financial Results for Q2 FY27 (Figures in ₹ Million)

  • Revenue from Operations: ₹7,318 in Q2 FY27 vs. ₹6,321 in Q2 FY26, a 15.8% YoY increase.
  • Adjusted EBITDA: ₹1,425 in Q2 FY27 vs. ₹1,215 in Q2 FY26, a 17.2% YoY increase.
  • EBITDA Margin: 19.7% in Q2 FY27, an improvement of 51 basis points from 19.2% in Q2 FY26.
  • PBT before extraordinary items: ₹301 in Q2 FY27 vs. ₹203 in Q2 FY26, a 48.1% YoY increase.
  • Adjusted Profit after Tax: ₹192 in Q2 FY27 vs. ₹212 in Q2 FY26, a 9.3% YoY decrease.

The Adjusted EBITDA excludes a loss of ₹61 million from the North Bangalore unit and an ESOP cost of ₹29.8 million for Q2 FY27. The Adjusted PAT is normalized for an extraordinary item of ₹116 million (₹99 million post-tax). The YoY decline in PAT is attributed to a favourable one-time deferred tax adjustment in Q2 FY26. All figures exclude the fertility business, which was divested effective June 30, 2026.

Consolidated Financial Results for H1 FY27 (Figures in ₹ Million)

  • Revenue from Operations: ₹14,100 in H1 FY27 vs. ₹12,303 in H1 FY26, a 14.6% YoY increase.
  • Adjusted EBITDA: ₹2,740 in H1 FY27 vs. ₹2,316 in H1 FY26, an 18.3% YoY increase.
  • EBITDA Margin: 19.7% in H1 FY27, an improvement of 84 basis points from 18.8% in H1 FY26.
  • PBT before extraordinary items: ₹553 in H1 FY27 vs. ₹328 in H1 FY26, a 68.4% YoY increase.
  • Adjusted Profit after Tax: ₹358 in H1 FY27 vs. ₹277 in H1 FY26, a 29.2% YoY increase.

For H1 FY27, Adjusted EBITDA also excludes an EPCG-related provision of ₹45.9 million and an H1 FY26 comparison excludes ESOP costs of ₹14.3 million and M&A-related costs of ₹25.6 million.

Operational and Business Highlights for Q2 FY27

  • Patient volumes increased by 9% YoY.
  • Average Revenue Per Patient (ARPP) grew by 7% YoY, driven by a favourable payor mix and higher contribution from advanced treatments.
  • Robotic surgeries increased by 37% YoY.
  • International business revenue grew approximately 54% YoY to ₹302 million, driven by increased patient volumes in radiation and medical oncology.
  • The share of non-institutional business improved by 325 basis points YoY to 69%.

Key Business Developments for Q2 FY27

  • Capacity Expansion: Added 25 operational beds (13 in Kenya, 7 in Kolkata, 5 in Nagpur), bringing total H1 FY27 bed additions to 146.
  • Advanced Technology Deployment: Operationalised an MR-LINAC system at North Bengaluru, a LINAC in Africa, and a cardiac robotic surgery system at HMS Ahmedabad.
  • Key Clinical Program Additions:
  • Performed first CAR-T cell therapy at HCC Ahmedabad.
  • Introduced robotic breast surgery at KR, robotic spine surgery at Rajkot, and Transoral Robotic Surgery (TORS) at Baroda.
  • Launched a 1,212-gene liquid biopsy panel and introduced two new nuclear medicine tracers at KR.

Management Commentary

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, emphasized the company's focus on advancing oncology care through clinical excellence, innovation, and research, specifically in multi-omics, organoid technology, cellular therapies including CAR-T, and longevity research.

Dr. Manish Mattoo, CEO, stated that the growth was driven by improved revenue mix, operational efficiencies, and an increase in high-complexity treatments. Priorities include improving asset utilisation, accelerating the ramp-up of newer facilities, enhancing productivity, and executing strategic capacity expansions.

The complete financial results are available on the company's website at https://www.hcgoncology.com/investor-relations/.

Contacts for Queries

  • Ravi Gothwal, Head Investor Relations, HealthCare Global Enterprises Limited: Ravi.gothwal@hcgel.com, Tel: +91 95996 55711.
  • Anoop Poojari / Suraj Digawalekar, CDR India: Ph: +91 98330 90434 / 98211 94418, Email: anoop@cdr-india.com / suraj@cdr-india.com.

Safe Harbor

The document contains forward-looking statements based on management's beliefs and expectations as of the date of the release, which are not guarantees of future performance and involve risks and uncertainties.